Han Bing, Ge Chang-Qing, Wang Li-Pu, Zhang Su-Fei, Li Heng-Zhou, Zhang Hong-Guang, Zhou Chen-Guang, Ji Guo-Hui, Yang Zheng, Zhang Liang
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Feb;34(2):153-6.
To observe the intervention effect of Leihong Granule (LG) in in-stent restenosis (ISR) after endovascular therapy for lower extremity arterial occlusive diseases (LEAOD).
Recruited 80 LEAOD patients who successfully underwent endovascular therapy (balloon dilation and stent implantation) were randomly assigned to two groups, the control group and the LG group, 40 in each group. Patients in the control group received basic treatment, while those in the LG group additionally took LG for 3 months. Plasma levels of IL-10, IL-18, CRP, and the intima-media thickness (IMT) of lower extremity artery were observed in the two groups between and after treatment. The rate of stent patency, ABI, intermittent claudication, rest pain, and the incidence of amputation the two groups were recorded and observed in the two groups.
In the control group, serum levels of IL-10, IL-18, CRP, and IMT were significantly higher one month after surgery than before surgery (P < 0.05). There was no significant difference in serum levels of IL-10, IL-18, CRP, or IMT between the two groups before surgery (P > 0.05). These indices were obviously lower in the LG group than in the control group after surgery (P < 0.05). Compared with the control group, the incidence rates of intermittent claudication and the rest pain at 6 months and 12 months after surgery significantly decreased (P < 0.05). The stent patency rate at 6 months and 12 months after surgery, and ABI were significantly higher than those of the control group (P < 0.05). There was no statistical difference in the amputation rate between the two groups (P > 0.05).
LG might effectively improve ischemic symptoms of affected limbs possibly through lowering the ISR rate after endovascular therapy for LEAOD through preventing immunosuppressive actions.
观察雷红颗粒（LG）对下肢动脉闭塞性疾病（LEAOD）血管内治疗后支架内再狭窄（ISR）的干预效果。
选取80例成功接受血管内治疗（球囊扩张和支架植入）的LEAOD患者，随机分为对照组和LG组，每组40例。对照组患者接受基础治疗，LG组患者在基础治疗的同时加服LG 3个月。观察两组治疗前后血浆白细胞介素-10（IL-10）、白细胞介素-18（IL-18）、C反应蛋白（CRP）水平及下肢动脉内膜中层厚度（IMT）。记录并观察两组支架通畅率、踝肱指数（ABI）、间歇性跛行、静息痛及截肢发生率。
对照组术后1个月血清IL-10、IL-18、CRP水平及IMT较术前显著升高（P<0.05）。两组术前血清IL-10、IL-18、CRP水平及IMT比较，差异无统计学意义（P>0.05）。术后LG组上述指标明显低于对照组（P<0.05）。与对照组比较，LG组术后6个月和12个月间歇性跛行及静息痛发生率显著降低（P<0.05）。术后6个月和12个月LG组支架通畅率及ABI明显高于对照组（P<0.05）。两组截肢率比较，差异无统计学意义（P>0.05）。
LG可能通过预防免疫抑制作用降低LEAOD血管内治疗后的ISR率，从而有效改善患肢缺血症状。
